Karthikeyan et al. use WHO pharmacovigilance data to evaluate cardiotoxicity profiles of CAR-T therapy and bispecific T-cell engagers. They find evidence of severe adverse cardiovascular events, including heart failure, in some patients treated with tisagenlecleucel.
- Badri Karthikeyan
- Sunitha Shyam Sunder
- Umesh C. Sharma